QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
NASDAQ:AGTC

Applied Genetic Technologies - AGTC Stock Forecast, Price & News

$0.43
0.00 (0.00%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.42
$0.43
50-Day Range
$0.35
$0.95
52-Week Range
$0.35
$3.73
Volume
1.09 million shs
Average Volume
793,766 shs
Market Capitalization
$21.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Applied Genetic Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3,401.4% Upside
$15.00 Price Target
Short Interest
Healthy
2.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
1.44mentions of Applied Genetic Technologies in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$9,609 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.49) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

125th out of 1,112 stocks

Biological Products, Except Diagnostic Industry

21st out of 175 stocks

AGTC stock logo

About Applied Genetic Technologies (NASDAQ:AGTC) Stock

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.

Applied Genetic Technologies Stock Performance

Shares of NASDAQ:AGTC remained flat at $0.43 during mid-day trading on Thursday. The company had a trading volume of 1,085,556 shares, compared to its average volume of 793,766. The firm has a market capitalization of $21.73 million, a price-to-earnings ratio of -0.29 and a beta of 1.32. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.73 and a current ratio of 2.73. Applied Genetic Technologies has a 1-year low of $0.35 and a 1-year high of $3.73. The stock's 50-day moving average price is $0.63 and its 200 day moving average price is $1.13.

Applied Genetic Technologies (NASDAQ:AGTC - Get Rating) last announced its earnings results on Monday, May 16th. The biotechnology company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.09. Equities research analysts expect that Applied Genetic Technologies will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on AGTC shares. StockNews.com started coverage on Applied Genetic Technologies in a research report on Sunday. They set a "sell" rating on the stock. Stifel Nicolaus restated a "buy" rating and issued a $10.00 price objective on shares of Applied Genetic Technologies in a report on Thursday, April 14th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Applied Genetic Technologies in a report on Tuesday, May 17th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $15.00.

Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Stock News Headlines

AGTC Announces Proposed Underwritten Public Offering
AGTC Announces Key Appointments to Leadership Team
AGTC to Participate in Upcoming Investor Conferences
See More Headlines
Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Company Calendar

Last Earnings
5/16/2022
Today
8/11/2022
Next Earnings (Estimated)
9/22/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGTC
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+3,401.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-57,830,000.00
Pretax Margin
-12,945.20%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$2.01 per share

Miscellaneous

Free Float
48,652,000
Market Cap
$21.73 million
Optionable
Optionable
Beta
1.32

Key Executives

  • Ms. Susan B. Washer (Age 61)
    Pres, CEO & Director
    Comp: $788.55k
  • Mr. Stephen W. Potter (Age 66)
    VP & Chief Bus. Officer
    Comp: $492.17k
  • Dr. Nicholas Muzyczka
    Co-Founder
  • Dr. Barry J. Byrne M.D.
    Ph.D., Co-Founder
  • Dr. William W. Hauswirth
    Co-Founder & Member of Ophthalmology Scientific Advisory Board
  • Dr. Richard Jude Samulski Ph.D.
    Co-Founder
  • Dr. Terence R. Flotte M.D.
    Co-Founder
  • Mr. Jonathan I. Lieber M.B.A. (Age 52)
    Chief Financial Officer
  • Mr. Gerald Anthony Reynolds
    Chief Accounting Officer, Principal Accounting Officer & Treasurer
  • Dr. Abraham Scaria Ph.D.
    Chief Scientific Officer













AGTC Stock - Frequently Asked Questions

Should I buy or sell Applied Genetic Technologies stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGTC shares.
View AGTC analyst ratings
or view top-rated stocks.

What is Applied Genetic Technologies' stock price forecast for 2022?

7 brokerages have issued 1 year target prices for Applied Genetic Technologies' shares. Their AGTC share price forecasts range from $10.00 to $24.00. On average, they anticipate the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 3,390.8% from the stock's current price.
View analysts price targets for AGTC
or view top-rated stocks among Wall Street analysts.

How have AGTC shares performed in 2022?

Applied Genetic Technologies' stock was trading at $1.90 at the beginning of the year. Since then, AGTC shares have decreased by 77.4% and is now trading at $0.4297.
View the best growth stocks for 2022 here
.

When is Applied Genetic Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, September 22nd 2022.
View our AGTC earnings forecast
.

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) posted its quarterly earnings results on Monday, May, 16th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.09.

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Who are Applied Genetic Technologies' major shareholders?

Applied Genetic Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.07%). Insiders that own company stock include Gerald Anthony Reynolds, Patrick Johan Hendrik Krol, Stephen W Potter and Susan B Washer.
View institutional ownership trends
.

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $0.43.

How much money does Applied Genetic Technologies make?

Applied Genetic Technologies (NASDAQ:AGTC) has a market capitalization of $21.80 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-57,830,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The official website for the company is www.agtc.com. The biotechnology company can be reached via phone at (386) 462-2204 or via email at david.carey@finnpartners.com.

This page (NASDAQ:AGTC) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.